{
  "simulation_id": "medqa_custom_configuration_10",
  "config": {
    "use_team_leadership": false,
    "use_closed_loop_comm": false,
    "use_mutual_monitoring": false,
    "use_shared_mental_model": false,
    "use_team_orientation": false,
    "use_mutual_trust": false,
    "mutual_trust_factor": 0.8,
    "use_recruitment": true,
    "recruitment_method": "adaptive",
    "recruitment_pool": "medical",
    "random_leader": false,
    "task": "MedQA Question"
  },
  "exchanges": [
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "1_Initial Assessment Team_Pulmonologist",
      "message": "ANSWER: D\n\n### Rationale:\nThis 36-year-old pregnant woman at 33 weeks gestation presents with acute respiratory distress and a confirmed high-probability pulmonary embolism (PE). Her clinical scenario is complicated by a history of **heparin-induced thrombocytopenia (HIT)**, which contraindicates the use of heparin-based anticoagulants, and her pregnancy, which precludes the use of direct oral anticoagulants (DOACs) such as dabigatran and apixaban due to their potential teratogenic effects and lack of safety data.\n\nThe systematic analysis of options, supported by all team members, is as follows:\n\n---\n\n### Option A: **Initiate long-term heparin**\n- **Strengths**: Heparin is a standard treatment for PE in pregnancy because it does not cross the placenta and is safe for the fetus.\n- **Weaknesses**: This patient has a history of HIT, a condition that makes the use of heparin absolutely contraindicated due to the risk of severe thrombocytopenia and thrombosis. Using heparin in this patient would be life-threatening.\n- **Conclusion**: This option is inappropriate.\n\n---\n\n### Option B: **Initiate dabigatran**\n- **Strengths**: Dabigatran is a direct thrombin inhibitor and does not rely on heparin pathways, theoretically bypassing the risk of HIT.\n- **Weaknesses**: Dabigatran is contraindicated in pregnancy because it crosses the placenta and poses risks of teratogenicity and fetal harm. Furthermore, it is not considered a first-line therapy for PE in pregnant patients.\n- **Conclusion**: This option is inappropriate.\n\n---\n\n### Option C: **Initiate apixaban**\n- **Strengths**: Apixaban is a direct factor Xa inhibitor and effective for PE management in non-pregnant patients.\n- **Weaknesses**: Like dabigatran, apixaban is contraindicated in pregnancy due to its ability to cross the placenta and the lack of sufficient safety data. It is not recommended for use in pregnant patients.\n- **Conclusion**: This option is inappropriate.\n\n---\n\n### Option D: **Consult IR for IVC filter placement**\n- **Strengths**: Placement of an inferior vena cava (IVC) filter is a non-pharmacologic option that prevents further embolization of thrombi to the lungs. This is particularly valuable for patients with contraindications to anticoagulation therapy, such as this patient with HIT and pregnancy. IVC filters provide immediate protection from further embolic events and are a viable temporary solution until anticoagulation can be considered postpartum.\n- **Weaknesses**: IVC filters do not address the underlying hypercoagulable state, and their long-term use is associated with risks such as filter thrombosis. However, in this case, the benefits of preventing further embolization outweigh these risks, especially given the limited pharmacologic options available.\n- **Conclusion**: This is the most appropriate choice for this patient, as it avoids the risks associated with both heparin and DOACs while effectively managing the acute risk of PE.\n\n---\n\n### Final Decision:\nAll team members, including specialists in obstetrics, emergency medicine, hematology, radiology, cardiology, and pharmacology, agree that **consulting interventional radiology (IR) for IVC filter placement** is the safest and most appropriate post-acute management strategy for this patient. This approach prioritizes both maternal and fetal safety while addressing the immediate risks of PE.\n\nThus, the final answer is **D. Consult IR for IVC filter placement**."
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "1_Initial Assessment Team_Obstetrician",
      "message": "ANSWER: D  \n\n### Rationale:  \nThis 36-year-old pregnant woman at 33 weeks of gestation with a confirmed diagnosis of pulmonary embolism (PE) presents a complex clinical scenario due to her history of **heparin-induced thrombocytopenia (HIT)** and pregnancy, which limits pharmacologic options for anticoagulation. After integrating the analyses from all team members, Option D\u2014consulting interventional radiology (IR) for **inferior vena cava (IVC) filter placement**\u2014is the most appropriate choice for her post-acute care.  \n\n#### Key Considerations:  \n1. **Pulmonary Embolism in Pregnancy**:  \n   - Pregnancy is a hypercoagulable state, increasing the risk of thromboembolism. Prompt management of PE is essential to prevent maternal and fetal complications.  \n\n2. **Heparin-Induced Thrombocytopenia (HIT)**:  \n   - HIT contraindicates the use of heparin or low molecular weight heparin (LMWH), which are the standard anticoagulants in pregnancy. Re-exposure to heparin could result in life-threatening thrombosis and thrombocytopenia, ruling out **Option A (Initiate long-term heparin)**.  \n\n3. **Direct Oral Anticoagulants (DOACs)**:  \n   - Both **dabigatran (Option B)** and **apixaban (Option C)** are contraindicated in pregnancy due to their ability to cross the placenta, potential teratogenicity, and lack of safety data. These medications are not considered safe or appropriate for use in pregnant patients.  \n\n4. **IVC Filter Placement**:  \n   - An IVC filter provides a non-pharmacologic option to mechanically prevent further embolization of thrombi to the lungs. This is particularly useful in patients who cannot receive anticoagulation therapy due to contraindications such as HIT or pregnancy.  \n   - While IVC filters do not treat the existing clot or address the underlying hypercoagulable state, they are an effective temporary solution to reduce the risk of further embolic events during pregnancy.  \n\n#### Strengths of Option D:  \n- **Maternal and Fetal Safety**: IVC filter placement avoids the risks associated with anticoagulants that are contraindicated in this patient (e.g., heparin and DOACs).  \n- **Efficacy**: The filter can significantly reduce the risk of recurrent PE, which is critical in this high-risk patient.  \n- **Temporary Measure**: The filter can be removed postpartum when anticoagulation therapy becomes safer and more feasible.  \n\n#### Weaknesses of Option D:  \n- IVC filters do not address the underlying hypercoagulable state, but this limitation is acceptable given the contraindications to anticoagulation in this patient.  \n\n### Conclusion:  \nGiven the patient\u2019s pregnancy, history of HIT, and confirmed PE, **consulting interventional radiology (IR) for IVC filter placement** is the safest and most appropriate post-acute management strategy. This approach prioritizes maternal and fetal safety while effectively preventing further embolization."
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "1_Initial Assessment Team_Emergency Medicine Physician",
      "message": "ANSWER: D  \n\n### Rationale:  \nAfter integrating the analyses provided by all team members and considering the patient's unique clinical scenario, **consulting interventional radiology (IR) for inferior vena cava (IVC) filter placement** is the most appropriate choice for post-acute management. This decision is based on the following key considerations:  \n\n---\n\n### Patient-Specific Factors:  \n1. **Pulmonary Embolism Diagnosis**: The patient has a confirmed high-probability pulmonary embolism (PE), which requires immediate intervention to prevent recurrence or worsening of embolic events.  \n\n2. **Pregnancy**: She is at 33 weeks gestation, and pregnancy significantly limits the use of certain medications, particularly direct oral anticoagulants (DOACs), due to their potential teratogenic effects and lack of safety data.  \n\n3. **Heparin-Induced Thrombocytopenia (HIT)**: The patient's history of HIT contraindicates the use of heparin-based anticoagulants, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH).  \n\n4. **Acute Respiratory Distress**: Her presentation highlights the need for immediate and safe intervention to mitigate the risk of further embolization.  \n\n---\n\n### Systematic Analysis of Options:  \n#### **Option A: Initiate long-term heparin**  \n- **Strengths**: Heparin is typically the first-line treatment for PE in pregnant patients due to its safety profile for the fetus.  \n- **Weaknesses**: Contraindicated due to the patient's history of HIT, which could lead to severe thrombocytopenia and thrombosis.  \n\n#### **Option B: Initiate dabigatran**  \n- **Strengths**: Dabigatran is a direct thrombin inhibitor that bypasses the heparin pathway, making it theoretically useful in HIT.  \n- **Weaknesses**: Contraindicated in pregnancy due to potential teratogenic effects and lack of sufficient safety data.  \n\n#### **Option C: Initiate apixaban**  \n- **Strengths**: Apixaban, a factor Xa inhibitor, avoids the heparin pathway and is effective for PE management in non-pregnant patients.  \n- **Weaknesses**: Contraindicated in pregnancy for the same reasons as dabigatran (placental transfer and fetal risks).  \n\n#### **Option D: Consult IR for IVC filter placement**  \n- **Strengths**: IVC filter placement is a non-pharmacologic intervention that prevents further embolization of thrombi to the lungs. This is particularly appropriate for patients with contraindications to anticoagulation, such as HIT, and when anticoagulation poses risks, as in pregnancy.  \n- **Weaknesses**: IVC filters do not address the underlying hypercoagulable state and are typically a temporary measure. However, in this scenario, they are the safest and most effective option.  \n\n---\n\n### Consensus:  \nAll team members agree that **Option D** is the safest and most appropriate choice for this patient. The contraindications to anticoagulation therapy (due to HIT and pregnancy) and the acute risk of embolization make IVC filter placement the optimal strategy for post-acute management. This approach prioritizes maternal and fetal safety while addressing the immediate risks of PE.  \n\n**ANSWER: D**"
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "2_Diagnostic Evidence Team_Hematologist",
      "message": "ANSWER: D  \n\n**Rationale:**  \nAfter integrating the analyses provided by all team members, the consensus is clear that **consulting interventional radiology (IR) for inferior vena cava (IVC) filter placement** is the most appropriate choice for managing this patient\u2019s post-acute care. Here\u2019s the reasoning:\n\n### Key Considerations:\n1. **Pulmonary Embolism Diagnosis**: The patient has a confirmed high-probability pulmonary embolism (PE) based on her elevated D-dimer and V/Q scan findings. PE requires immediate intervention to prevent recurrence and complications such as worsening respiratory distress or fatal embolism.\n\n2. **Pregnancy**: At 33 weeks gestation, the patient\u2019s pregnancy limits pharmacologic options for anticoagulation. Direct oral anticoagulants (DOACs) such as dabigatran (Option B) and apixaban (Option C) are contraindicated due to potential teratogenic effects and insufficient safety data during pregnancy. The safety of the fetus must be prioritized.\n\n3. **Heparin-Induced Thrombocytopenia (HIT)**: The patient\u2019s history of HIT contraindicates the use of heparin or low molecular weight heparin (LMWH), which are typically first-line anticoagulants in pregnancy. Re-exposure to heparin could trigger life-threatening thrombocytopenia and thrombosis, eliminating Option A (Initiate long-term heparin) as a viable choice.\n\n4. **Acute Respiratory Distress**: The patient\u2019s acute presentation underscores the need for immediate intervention to prevent further embolization and worsening of her clinical status. An IVC filter offers mechanical protection by trapping thrombi from the lower extremities before they reach the lungs, mitigating the risk of recurrent PE.\n\n### Systematic Analysis of Options:\n- **Option A: Initiate long-term heparin**  \n   - Contraindicated due to the patient\u2019s history of HIT.  \n\n- **Option B: Initiate dabigatran**  \n   - Contraindicated during pregnancy due to teratogenic risks and insufficient safety data.  \n\n- **Option C: Initiate apixaban**  \n   - Contraindicated during pregnancy for the same reasons as dabigatran.  \n\n- **Option D: Consult IR for IVC filter placement**  \n   - Suitable for patients with contraindications to anticoagulation therapy, such as HIT or pregnancy. IVC filters provide immediate protection from further embolization, making this the safest and most effective choice in this patient\u2019s unique clinical scenario.\n\n### Final Conclusion:\nGiven the patient\u2019s pregnancy, history of HIT, and confirmed PE diagnosis, anticoagulation therapy is contraindicated. Placement of an IVC filter is the safest and most appropriate post-acute management strategy, as it prevents further embolization while avoiding harm to both the mother and fetus. This approach is supported by the consensus of all team members and prioritizes maternal and fetal safety in a high-risk situation."
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "2_Diagnostic Evidence Team_Radiologist",
      "message": "ANSWER: D  \n\n**Rationale:**  \n\nThis 36-year-old pregnant woman at 33 weeks gestation has a confirmed diagnosis of pulmonary embolism (PE) based on her elevated D-dimer and high-probability V/Q scan. Her medical history is complicated by heparin-induced thrombocytopenia (HIT), which contraindicates the use of heparin-based anticoagulants, and her pregnancy, which limits the use of direct oral anticoagulants (DOACs) such as dabigatran and apixaban due to their potential teratogenic effects and lack of safety data.  \n\n### Systematic Analysis of Options:  \n\n1. **Option A: Initiate long-term heparin**  \n   - **Strengths:** Heparin is often the first-line treatment for PE in pregnancy because it does not cross the placenta and is safe for the fetus.  \n   - **Weaknesses:** This patient has a history of HIT, a contraindication to heparin use. Re-exposure to heparin could lead to life-threatening thrombocytopenia and thrombosis.  \n   - **Conclusion:** This option is inappropriate due to the patient's history of HIT.  \n\n2. **Option B: Initiate dabigatran**  \n   - **Strengths:** Dabigatran is a direct thrombin inhibitor and bypasses the mechanisms affected by HIT.  \n   - **Weaknesses:** Dabigatran is contraindicated in pregnancy due to its potential to cross the placenta, teratogenic effects, and lack of robust safety data. It is not a suitable option for this patient.  \n   - **Conclusion:** This option is inappropriate due to the patient's pregnancy.  \n\n3. **Option C: Initiate apixaban**  \n   - **Strengths:** Apixaban, a factor Xa inhibitor, is effective for treating PE in non-pregnant patients.  \n   - **Weaknesses:** Like dabigatran, apixaban is contraindicated in pregnancy because it crosses the placenta and poses risks to the fetus. It is not recommended for use in pregnant patients.  \n   - **Conclusion:** This option is inappropriate due to the patient's pregnancy.  \n\n4. **Option D: Consult IR for IVC filter placement**  \n   - **Strengths:** Placement of an inferior vena cava (IVC) filter is a mechanical intervention that prevents embolization of thrombi to the lungs. It is particularly useful in patients who cannot receive anticoagulation therapy due to contraindications, such as HIT, or when anticoagulation poses significant risks, as in pregnancy. IVC filters are a safe and effective option in this scenario, providing immediate protection from further embolization during the remainder of the pregnancy.  \n   - **Weaknesses:** IVC filters do not treat the underlying hypercoagulable state and are typically reserved for temporary use. However, given this patient's contraindications to anticoagulation, an IVC filter is the most appropriate choice.  \n\n### Integrated Conclusion:  \n\nAll team members agree that consulting interventional radiology (IR) for IVC filter placement is the safest and most appropriate post-acute management for this patient. This approach avoids the risks associated with anticoagulants contraindicated due to her HIT and pregnancy, while effectively addressing the immediate risk of further embolization.  \n\nThus, **Option D** is the correct choice."
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "2_Diagnostic Evidence Team_Endocrinologist",
      "message": "ANSWER: D\n\n### Rationale:\n\nThis 36-year-old pregnant woman at 33 weeks of gestation has been diagnosed with a high-probability pulmonary embolism (PE) based on her V/Q scan. Her medical history is significant for **heparin-induced thrombocytopenia (HIT)**, which precludes the use of heparin or low molecular weight heparin (LMWH). Additionally, her pregnancy limits the use of direct oral anticoagulants (DOACs) like dabigatran and apixaban due to their potential teratogenic effects and insufficient safety data. Therefore, the safest and most appropriate post-acute management strategy is **consulting interventional radiology (IR) for inferior vena cava (IVC) filter placement**. \n\n---\n\n### Integration of Insights:\n\n1. **Contraindication to Heparin (Option A)**:\n   - All team members agree that the patient's history of HIT makes the use of heparin or LMWH contraindicated. Re-exposure to heparin could trigger a recurrence of HIT, leading to severe thrombocytopenia and thrombotic complications. While heparin is generally safe for use during pregnancy, it is not an option in this patient.\n\n2. **Contraindication to DOACs (Options B and C)**:\n   - Both dabigatran and apixaban are contraindicated during pregnancy due to their ability to cross the placenta and their potential teratogenic effects. All team members highlighted the lack of safety data for DOACs in pregnancy, making these options inappropriate for this patient.\n\n3. **Suitability of IVC Filter Placement (Option D)**:\n   - All team members concurred that IVC filter placement is the most appropriate choice for this patient. Given her contraindications to anticoagulation (HIT and pregnancy), an IVC filter provides a mechanical solution to prevent further embolization of thrombi to the lungs. While IVC filters do not address the underlying hypercoagulable state, they are a safe and effective temporary measure in this high-risk scenario. The placement of an IVC filter minimizes the risk of recurrent PE while avoiding harm to both the mother and fetus.\n\n---\n\n### Final Decision:\nGiven the patient's unique clinical context\u2014pregnancy, history of HIT, and confirmed PE\u2014**consulting interventional radiology for IVC filter placement** is the safest and most effective post-acute management strategy. This approach prioritizes maternal and fetal safety while addressing the immediate risk of further embolism."
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "3_Final Review and Decision Team_Obstetrician",
      "message": "ANSWER: D  \n\n### Rationale:  \nAfter integrating the analyses from all team members and considering the patient's clinical presentation and history, the most appropriate choice for post-acute management is **consulting interventional radiology (IR) for inferior vena cava (IVC) filter placement**.  \n\n---\n\n### Key Patient Considerations:  \n1. **Pregnancy at 33 Weeks Gestation**:  \n   - The patient is in her third trimester, a time when anticoagulation therapy must be carefully selected to avoid harm to the fetus.  \n   - Direct oral anticoagulants (DOACs) such as dabigatran and apixaban are contraindicated during pregnancy because they cross the placenta and pose potential teratogenic risks.  \n\n2. **History of Heparin-Induced Thrombocytopenia (HIT)**:  \n   - This contraindicates the use of heparin or low molecular weight heparin (LMWH), which are otherwise preferred anticoagulants in pregnancy.  \n   - Re-exposure to heparin could trigger a recurrence of HIT, leading to severe thrombocytopenia and thrombotic complications.  \n\n3. **Pulmonary Embolism Diagnosis**:  \n   - The patient has a confirmed high-probability pulmonary embolism (PE) based on her V/Q scan and elevated D-dimer.  \n   - Acute respiratory distress highlights the urgency of preventing further embolization.  \n\n4. **Contraindications to Anticoagulation**:  \n   - With heparin contraindicated due to HIT and DOACs contraindicated due to pregnancy, pharmacologic anticoagulation is not a viable option.  \n\n---\n\n### Systematic Analysis of Options:  \n- **A. Initiate long-term heparin**:  \n   - While heparin is safe for the fetus, it is contraindicated in this patient due to her history of HIT. Administering heparin could result in severe complications, making this option inappropriate.  \n\n- **B. Initiate dabigatran**:  \n   - Dabigatran is contraindicated in pregnancy because it crosses the placenta and has insufficient safety data. It is not a safe or appropriate choice for this patient.  \n\n- **C. Initiate apixaban**:  \n   - Like dabigatran, apixaban is contraindicated in pregnancy due to its potential teratogenic risks and lack of robust safety data. This option is also inappropriate.  \n\n- **D. Consult IR for IVC filter placement**:  \n   - An IVC filter is a mechanical intervention that prevents further embolization of thrombi to the lungs.  \n   - It is particularly useful in patients with contraindications to anticoagulation, such as this patient with HIT and pregnancy.  \n   - While IVC filters do not address the underlying hypercoagulable state, they are a safe and effective temporary measure in this scenario.  \n\n---\n\n### Integration of Team Insights:  \nAll team members, including specialists in pulmonology, obstetrics, hematology, radiology, cardiology, and pharmacology, unanimously identified **Option D** as the most appropriate choice. Their analyses highlighted the contraindications to pharmacologic anticoagulation and the suitability of an IVC filter as a non-pharmacologic intervention to prevent further embolization.  \n\n---\n\n### Conclusion:  \nGiven the patient\u2019s pregnancy, history of HIT, and confirmed PE, **consulting interventional radiology for IVC filter placement** is the safest and most effective post-acute management strategy. This approach minimizes maternal and fetal risks while addressing the immediate threat of further embolization."
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "3_Final Review and Decision Team_Cardiologist",
      "message": "ANSWER: D  \n\n### Final Rationale:  \nAfter careful consideration of the perspectives from all team members, the most appropriate choice for post-acute management in this patient is **consulting interventional radiology (IR) for inferior vena cava (IVC) filter placement**. This decision is based on the following integrated analysis:\n\n---\n\n### **Key Patient Considerations:**  \n1. **Pulmonary Embolism Diagnosis:**  \n   The patient has a confirmed high-probability pulmonary embolism (PE) based on her V/Q scan and elevated D-dimer. PE requires immediate intervention to prevent further embolic events and manage the acute risk of mortality.  \n\n2. **History of Heparin-Induced Thrombocytopenia (HIT):**  \n   HIT is a contraindication to heparin and low-molecular-weight heparin (LMWH) use due to the risk of severe thrombocytopenia and thrombosis. This eliminates **Option A (Initiate long-term heparin)** as a viable treatment.  \n\n3. **Pregnancy:**  \n   At week 33 of gestation, the patient\u2019s pregnancy further limits treatment options. Direct oral anticoagulants (DOACs) such as **dabigatran (Option B)** and **apixaban (Option C)** are contraindicated due to their ability to cross the placenta, posing potential teratogenic risks to the fetus and insufficient safety data for use during pregnancy.  \n\n4. **Acute Respiratory Distress:**  \n   The patient\u2019s acute presentation with respiratory distress highlights the urgency of preventing further embolization. Given her contraindications to pharmacologic anticoagulation, a mechanical solution such as an IVC filter is the safest and most effective option.  \n\n---\n\n### **Systematic Analysis of Options:**  \n#### **A. Initiate long-term heparin:**  \n   - **Strengths:** Heparin is a standard anticoagulant for PE in pregnancy due to its safety for the fetus.  \n   - **Weaknesses:** Contraindicated in this patient due to her history of HIT. Re-exposure to heparin could trigger severe thrombocytopenia and thrombotic complications.  \n   - **Conclusion:** This option is not appropriate.  \n\n#### **B. Initiate dabigatran:**  \n   - **Strengths:** Dabigatran is a direct thrombin inhibitor and bypasses the heparin pathway, making it theoretically useful in patients with HIT.  \n   - **Weaknesses:** Contraindicated in pregnancy due to potential teratogenic effects and lack of safety data. This option is not appropriate for a pregnant patient.  \n   - **Conclusion:** This option is not appropriate.  \n\n#### **C. Initiate apixaban:**  \n   - **Strengths:** Apixaban is a direct factor Xa inhibitor and bypasses the heparin pathway, which avoids the risk of HIT.  \n   - **Weaknesses:** Like dabigatran, apixaban is contraindicated in pregnancy due to its ability to cross the placenta and potential teratogenic effects. This option is not appropriate for a pregnant patient.  \n   - **Conclusion:** This option is not appropriate.  \n\n#### **D. Consult IR for IVC filter placement:**  \n   - **Strengths:** IVC filter placement is a non-pharmacologic intervention that mechanically prevents further embolization of thrombi to the lungs. It is particularly useful in high-risk patients who cannot receive anticoagulation therapy due to contraindications (e.g., HIT) or pregnancy-related concerns. This approach is safe for both the mother and fetus and provides immediate protection from embolic events.  \n   - **Weaknesses:** IVC filters do not treat the existing clot and are typically used as a temporary measure. However, in this patient\u2019s case, the contraindications to anticoagulation justify their use.  \n   - **Conclusion:** This is the most appropriate choice for post-acute management in this patient.  \n\n---\n\n### **Consensus from All Team Members:**  \nAll team members agree that **Option D (Consult IR for IVC filter placement)** is the safest and most effective choice for this patient. The contraindications to heparin and DOACs due to her history of HIT and pregnancy leave IVC filter placement as the only viable option to prevent further embolization during the remainder of her pregnancy.  \n\n---\n\n### **Final Conclusion:**  \nGiven the patient\u2019s pregnancy, history of HIT, and confirmed PE diagnosis, **consulting interventional radiology for IVC filter placement** is the most appropriate post-acute management strategy. This approach prioritizes maternal and fetal safety while addressing the acute risk of further embolism.  \n\n**ANSWER: D**"
    },
    {
      "type": "collaborative_discussion",
      "communication": "standard",
      "sender": "3_Final Review and Decision Team_Pharmacologist",
      "message": "ANSWER: D  \n\n### Rationale:  \nAfter reviewing all perspectives and integrating insights from each specialty, the most appropriate post-acute management for this patient is to **consult interventional radiology (IR) for IVC filter placement**. This decision is based on the following key points:  \n\n### Patient-Specific Factors:  \n1. **Confirmed Pulmonary Embolism (PE)**: The patient has a high-probability PE based on her V/Q scan and clinical presentation. This requires immediate intervention to prevent further embolization and associated complications.  \n2. **Heparin-Induced Thrombocytopenia (HIT)**: The patient\u2019s history of HIT contraindicates the use of heparin or low molecular weight heparin (LMWH), which are standard anticoagulants for PE, especially during pregnancy.  \n3. **Pregnancy (33 Weeks Gestation)**: Pregnancy significantly limits pharmacologic options due to potential teratogenic effects and safety concerns for the fetus. Direct oral anticoagulants (DOACs) such as dabigatran and apixaban are contraindicated in pregnancy.  \n4. **Acute Respiratory Distress**: The patient's acute presentation underscores the need for immediate and effective prevention of further thromboembolic events.  \n\n### Option Analysis:  \n- **A. Initiate long-term heparin**:  \n   - **Contraindicated** due to the patient\u2019s history of HIT, which poses a risk of severe thrombocytopenia and thrombosis upon re-exposure to heparin.  \n\n- **B. Initiate dabigatran**:  \n   - **Inappropriate** as dabigatran is contraindicated in pregnancy due to its potential teratogenic effects and lack of safety data.  \n\n- **C. Initiate apixaban**:  \n   - **Inappropriate** for the same reasons as dabigatran. Apixaban crosses the placenta and is not recommended in pregnancy.  \n\n- **D. Consult IR for IVC filter placement**:  \n   - **Appropriate** because IVC filters provide mechanical protection by preventing thrombi from traveling to the lungs, effectively mitigating the risk of recurrent PE. This is particularly useful in patients with contraindications to anticoagulation therapy, such as this patient with HIT and pregnancy. While IVC filters are typically a temporary solution, they are a safe and effective option for this patient during the remainder of her pregnancy.  \n\n### Integration of Insights:  \nAll team members, including pulmonology, obstetrics, hematology, radiology, emergency medicine, and cardiology, unanimously agree that IVC filter placement is the safest and most effective management option. This consensus is based on the patient\u2019s unique contraindications to anticoagulants and her high-risk pregnancy.  \n\n### Conclusion:  \nGiven the patient\u2019s clinical situation, history of HIT, and contraindications to pharmacologic anticoagulation during pregnancy, the best course of action is to **consult interventional radiology for IVC filter placement**. This approach prioritizes both maternal and fetal safety while addressing the acute risks of PE."
    }
  ],
  "decision_results": {
    "majority_voting": {
      "method": "majority_voting",
      "winning_option": "D",
      "vote_counts": {
        "D": 3
      },
      "total_votes": 3,
      "confidence": 1.0
    },
    "weighted_voting": {
      "method": "weighted_voting",
      "winning_option": "D",
      "vote_counts": {
        "D": 3
      },
      "weighted_votes": {
        "D": 3.9000000000000004
      },
      "total_votes": 3,
      "confidence": 1.0
    },
    "borda_count": {
      "method": "borda_count",
      "winning_option": "D",
      "borda_scores": {
        "A": 0,
        "B": 0,
        "C": 0,
        "D": 9
      },
      "total_possible_score": 9.0,
      "confidence": 1.0
    },
    "mdt_process": {
      "team_decisions": {
        "1_Initial Assessment Team": {
          "method": "majority_voting",
          "winning_option": "D",
          "vote_counts": {
            "D": 3
          },
          "total_votes": 3,
          "confidence": 1.0
        },
        "2_Diagnostic Evidence Team": {
          "method": "majority_voting",
          "winning_option": "D",
          "vote_counts": {
            "D": 3
          },
          "total_votes": 3,
          "confidence": 1.0
        },
        "3_Final Review and Decision Team": {
          "method": "majority_voting",
          "winning_option": "D",
          "vote_counts": {
            "D": 3
          },
          "total_votes": 3,
          "confidence": 1.0
        }
      },
      "decision_team": "3_Final Review and Decision Team"
    }
  },
  "teamwork_metrics": {}
}